BRAF Mutation Analysis Assay is based on PCR amplification and detection of target DNA using complementary primer pairs and oligonucleotide probes labeled with fluorsescent dyes. This assay is designed to detect V600 mutations E, K, D, R, and G with an analytical sensitivity of 1% for V600E, V600K and V600R and 5% for V600D and V600G. For solid tumors, tumor enrichment is performed before extraction. Expanded coverage for BRAF exons 11 & 15 is available in the RAS/RAF Panel. Testing is available separately or in combination with HRAS, KRAS, and NRAS in the RAS/RAF Panel.
BRAF mutations are frequently found in human cancers. They are found most frequently in melanoma (50-70%), papillary thyroid cancer (36-40%) and almost all hairy cell leukemia. BRAF mutations are also found with low frequency in colorectal cancer (5-12%), non-small cell lung cancer (NSCLC), acute myeloid leukemia (AML), glioma, sarcoma, breast cancer, hepatoma, and ovarian cancer. The presence of BRAF V600E mutation in colon cancer with microsatellite instability (MSI) provides strong support for sporadic (non-Lynch) colon cancer.
- FFPE solid tumor tissue: Paraffin block is preferred. Alternatively, send 1 H&E slide plus 5-10 unstained slides cut at 5 or more microns. Please use positively-charged slides and 10% NBF fixative. Do not use zinc fixatives.
- Peripheral blood: 5 mL in EDTA tube.
- Bone marrow: 2 mL in EDTA tube.
Note: Test is DNA-based. Please select Extract & Hold - DNA if specimen hold service is desired.
Use cold pack for transport, making sure cold pack is not in direct contact with specimen. All slides can be packed at room temperature.
7 days